csbr
- Creatore Discussione axelvento
- Data di inizio
lo so, ho letto la news ieri, l'ho anche postata sul 3d "reverse merger" ma poi l'ho anche tolta perche' mi sembrava la solita sparata (era una mail arrivata ad un folista iu-ess-eiaxelvento ha scritto:meta' sono riuscito a venderle... ,12 ,16
la cosa interessante che sono entrati questi due dott.per cambiare
l'azienda diventare"penso un biotec"....
al momento non ha business
)era questa:
http://www.investorshub.com/boards/read_msg.asp?message_id=16077727
Ultima modifica:
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
ottima news
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Recent Highlights:
Quarterly revenue of $3.02 million
Signing of partnership with Teva
Regulatory approval from New York Department of Health
Hiring of two senior executives
Joel Ackerman, Champions Oncology CEO, stated, "The first fiscal quarter of 2014 was a great start for the year. Our financial results were strong in both segments, driven by robust growth and margins. We also had a number of accomplishments that don't show up in the numbers but set the stage for the future."
Revenue was $3.02 million, as compared to $2.1 million for the three months ended July 31, 2012, an increase of 43%. Total operating expenses were $3.8 million, as compared to $3.7 million for the three months ended July 31, 2012.
Champions reported a loss from operations of $0.77 million as compared to a loss from operations of $1.6 million for the three months ended July 31, 2012. Excluding stock-based compensation of $0.55 million and $0.74 million for the three months ended July 31, 2013 and 2012, Champions recognized a loss from operations of $0.2 million and a loss from operations of $0.9 million for three months ended July 31, 2013 and 2012, respectively.
Operating Results
Personalized Oncology Solutions (POS):
The number of implants during the quarter was 65, an increase of 141% over the same period last year. The increase in implants is the result of growing visibility with patients and physicians, the reduction in patient costs per implant and expanding our international operations. The number of patients for whom studies were completed was 22 for the quarter, an increase of 69% over the same period last year. The increase in patient studies is the result of higher implant volumes in the recent quarters which lead to studies in subsequent quarters. POS revenues were $0.6 million and $0.9 million for the three months ended July 31, 2013 and 2012, respectively, a decrease of $0.3 million or 32.2%. The decrease is due to the decrease in non-core physician panel revenue of $0.3 million. This is due to the strategic decision to focus on our core products and services.
POS cost of sales was $0.79 million and $0.77 million for the three months ended July 31, 2013 and 2012, respectively, an increase of $0.02 million, or 2.7%. For the three months ended July 31, 2013 and 2012, gross margins for POS were -27.5% and 16%, respectively. The gross margin in this business segment fluctuates based on a number of factors including business mix, pricing and volumes.
Translational Oncology Solutions (TOS):
TOS revenues were $2.39 million and $1.18 million for the three months ended July 31, 2013 and 2012, respectively, an increase of $1.21 million, or 102%.
TOS cost of sales was $0.88 million and $0.7 million for the three months ended July 31, 2013 and 2012, respectively, an increase of $0.2 million, or 26%. For the three months ended July 31, 2013 and 2012, gross margins for TOS were 63% and 41%. The increase in gross margin is due to the leveraging of the fixed component of cost of sales over a higher revenue amount and the absorption of certain costs associated with this quarter's revenue in previous quarters.
Research and development expense was $0.4 million for three months ended July 31, 2013 and 2012, respectively. Sales and marketing expense was $0.6 million and $0.7 million for the three months ended July 31, 2013 and 2012, respectively, a decrease of $0.1 million, or 9.4%. General and administrative expense was $1.07 million and $1.14 million for the three months ended July 31, 2013 and 2012, respectively, a decrease of $0.07 million, or 5.9% due to the decrease in stock compensation expense.
Conference Call Information:
The Company will host a conference call on Friday, September 13, 2013, at 8:30 a.m. ET to discuss its first quarter financial results. To access the conference call, domestic participants should dial 800-875-3456, Canadian participants should dial 800-648-0973, and international participants should dial 302-607-2001. The participant passcode is "Champions Oncology."
Full details of the Company's financial results will be available in the Company's Form 10-K at Finding the Right Patients and the Right Drugs..
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Recent Highlights:
Quarterly revenue of $3.02 million
Signing of partnership with Teva
Regulatory approval from New York Department of Health
Hiring of two senior executives
Joel Ackerman, Champions Oncology CEO, stated, "The first fiscal quarter of 2014 was a great start for the year. Our financial results were strong in both segments, driven by robust growth and margins. We also had a number of accomplishments that don't show up in the numbers but set the stage for the future."
Revenue was $3.02 million, as compared to $2.1 million for the three months ended July 31, 2012, an increase of 43%. Total operating expenses were $3.8 million, as compared to $3.7 million for the three months ended July 31, 2012.
Champions reported a loss from operations of $0.77 million as compared to a loss from operations of $1.6 million for the three months ended July 31, 2012. Excluding stock-based compensation of $0.55 million and $0.74 million for the three months ended July 31, 2013 and 2012, Champions recognized a loss from operations of $0.2 million and a loss from operations of $0.9 million for three months ended July 31, 2013 and 2012, respectively.
Operating Results
Personalized Oncology Solutions (POS):
The number of implants during the quarter was 65, an increase of 141% over the same period last year. The increase in implants is the result of growing visibility with patients and physicians, the reduction in patient costs per implant and expanding our international operations. The number of patients for whom studies were completed was 22 for the quarter, an increase of 69% over the same period last year. The increase in patient studies is the result of higher implant volumes in the recent quarters which lead to studies in subsequent quarters. POS revenues were $0.6 million and $0.9 million for the three months ended July 31, 2013 and 2012, respectively, a decrease of $0.3 million or 32.2%. The decrease is due to the decrease in non-core physician panel revenue of $0.3 million. This is due to the strategic decision to focus on our core products and services.
POS cost of sales was $0.79 million and $0.77 million for the three months ended July 31, 2013 and 2012, respectively, an increase of $0.02 million, or 2.7%. For the three months ended July 31, 2013 and 2012, gross margins for POS were -27.5% and 16%, respectively. The gross margin in this business segment fluctuates based on a number of factors including business mix, pricing and volumes.
Translational Oncology Solutions (TOS):
TOS revenues were $2.39 million and $1.18 million for the three months ended July 31, 2013 and 2012, respectively, an increase of $1.21 million, or 102%.
TOS cost of sales was $0.88 million and $0.7 million for the three months ended July 31, 2013 and 2012, respectively, an increase of $0.2 million, or 26%. For the three months ended July 31, 2013 and 2012, gross margins for TOS were 63% and 41%. The increase in gross margin is due to the leveraging of the fixed component of cost of sales over a higher revenue amount and the absorption of certain costs associated with this quarter's revenue in previous quarters.
Research and development expense was $0.4 million for three months ended July 31, 2013 and 2012, respectively. Sales and marketing expense was $0.6 million and $0.7 million for the three months ended July 31, 2013 and 2012, respectively, a decrease of $0.1 million, or 9.4%. General and administrative expense was $1.07 million and $1.14 million for the three months ended July 31, 2013 and 2012, respectively, a decrease of $0.07 million, or 5.9% due to the decrease in stock compensation expense.
Conference Call Information:
The Company will host a conference call on Friday, September 13, 2013, at 8:30 a.m. ET to discuss its first quarter financial results. To access the conference call, domestic participants should dial 800-875-3456, Canadian participants should dial 800-648-0973, and international participants should dial 302-607-2001. The participant passcode is "Champions Oncology."
Full details of the Company's financial results will be available in the Company's Form 10-K at Finding the Right Patients and the Right Drugs..